Skip to content

Investors Overview

Esperion is a pharmaceutical company passionately committed to developing and commercializing non-statin, once-daily, oral therapies to lower elevated low-density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid is being developed as a once-daily, oral inhibitor of ATP Citrate Lyase (ACL), and is designed to bring a targeted mechanism of action to address patients’ unmet medical needs.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics () on
Last Price Change open Day High 52-Week High
Volume Previous Close Day Low 52-Week Low

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results
ANN ARBOR, Mich., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the second quarter ended June 30, 2019. “This year continues the momentum we’ve come to expect from our team of Lipid Management
Toggle Summary Esperion to Present at the BTIG Biotechnology Conference
ANN ARBOR, Mich., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will participate in a lipid panel discussion with investors at the BTIG Biotechnology Conference in New York, NY on Monday, August 12, 2019 at 11:00 a.m. Eastern Time.
Toggle Summary Esperion to Report Second Quarter 2019 Financial Results August 8, 2019
ANN ARBOR, Mich., July 30, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets open. Bempedoic Acid Bempedoic acid is our lead, non-statin, orally available, once-daily, LDL-C
Toggle Summary Esperion and Oberland Capital Announce $200 Million Funding Agreement
- $125 Million Upfront, $25 Million Upon FDA Approval, and $50 Million at Esperion’s Option After Launch - - Initial Mid-Single Digit Repayment Rate on U.S. Revenue to Step Down to Less than One Percent Rate Upon Certain Revenue Achievements - - Esperion Reacquires 100% Revenue Rights Upon
Toggle Summary Esperion Announces the Appointment of Tracy M. Woody to Board of Directors
ANN ARBOR, Mich., May 30, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Tracy M. Woody as a Class I director, with a term expiring at the 2020 meeting of stockholders. "On behalf of the Lipid Management team and our directors, I am very pleased to welcome Tracy
Load More